Meeting
2016 ASCO Annual Meeting
Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.
Authors
Bernardo Leon Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Bernardo Leon Rapoport , Lee Steven Schwartzberg , Sujata Arora , Daniel Powers , Karin Jordan , Rudolph M. Navari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01500226, NCT01499849, NCT01500213
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10122)
DOI
10.1200/JCO.2016.34.15_suppl.10122
Abstract #
10122
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for control of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.
First Author: Bernardo Leon Rapoport
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers.
First Author: Rudolph M. Navari
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
First Author: Rudolph M. Navari
Poster
2014 ASCO Annual Meeting
Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC).
First Author: Laszlo Urban